Monitor early prescription data and physician adoption of the OBI formulation over the next 2-4 quarters. Key competitive risk is Johnson & Johnson's Darzalex (daratumumab), which also has SC formulations. Any market share shifts will be visible in Sanofi's quarterly oncology segment reporting.
Price Chart
Executive Summary
Sanofi announced FDA approval of subcutaneous Sarclisa Escena (isatuximab-irfc) for all existing multiple myeloma indications, making it the first anticancer treatment administered via an on-body injector. The approval, supported by the Phase 3 IRAKLIA study showing non-inferior efficacy with shorter administration time and fewer infusion reactions, strengthens Sarclisa's competitive positioning and may drive adoption through improved patient convenience.
Key Facts
- FDA approved subcutaneous Sarclisa Escena across all existing IV indications for multiple myeloma
- First anticancer treatment to be administered via an on-body injector (CirCLIQ OBI)
- IRAKLIA Phase 3 study demonstrated non-inferior ORR (71.1% SC vs 70.5% IV) with significantly fewer systemic administration reactions (1.5% vs 25%)
- Sarclisa has been prescribed to over 70,000 patients worldwide and is approved in nearly 60 countries
Financial Impact
Positive but unquantified; the SC formulation may expand Sarclisa's addressable patient population and improve treatment convenience, potentially increasing market share against competitors like Darzalex. No specific revenue guidance provided.
Risk Factors
- Competition from Darzalex SC (J&J) which already has a subcutaneous formulation
- Adoption may be slower if providers are reluctant to adopt new administration devices
- No incremental efficacy benefit over IV formulation; differentiation is purely convenience-based
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001193125-26-306689 |
| Document: d106024d6k.htm | 0001193125-26-306689 |
| Document: 0001193125-26-306689-index-headers.html | 0001193125-26-306689 |
| Document: 0001193125-26-306689-index.html | 0001193125-26-306689 |
| Document: 0001193125-26-306689.txt | 0001193125-26-306689 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 31, 2026 4w ago | Court Ruling | $44.36 $40.74 | ▼ −8.16% | ▼ −7.97% | $39.92 (−10.01%) |
Aug 17, 2026 6w ago | Court Ruling | $44.41 $42.40 | ▼ −4.53% | ▼ −2.55% | $39.92 (−10.11%) |
Aug 12, 2026 7w ago | Court Ruling | $43.71 $42.72 | ▼ −2.26% | ▼ −0.37% | $39.92 (−8.67%) |
Jul 31, 2026 9w ago | Court Ruling | $43.08 $44.82 | ▲ +4.04% | ▲ +1.05% | $39.92 (−7.34%) |
Jul 30, 2026 9w ago | 6-K | $42.89 $44.84 | ▲ +4.55% | ▲ +0.58% | $39.92 (−6.92%) |
Jul 27, 2026 9w ago | 6-K | $44.00 $45.69 | ▼ −3.84% | ▼ −0.54% | $39.92 (+9.27%) |
Jul 17, 2026 11w ago | 6-K | $44.66 $43.72 | ▼ −2.10% | ▼ −6.55% | $39.92 (−10.61%) |
Jul 7, 2026 12w ago | 6-K | $42.98 $42.95 | ▼ −0.07% | ▼ −1.40% | $39.92 (−7.12%) |
Apr 13, 2026 24w ago | Court Ruling | $44.49 $42.50 | ▼ −4.48% | ▼ −12.20% | $39.92 (−10.28%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access